| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8244321 | International Journal of Radiation Oncology*Biology*Physics | 2006 | 9 Pages |
Abstract
Conclusions: Radioimmunotherapy is safe and effective in many patients with B-cell NHL. 90Y ibritumomab tiuxetan and 131I tositumomab can produce clinically meaningful and durable responses even in patients in whom chemotherapy has failed. Treatment with RIT requires a multispecialty approach and close communication between the radiation oncologist and other members of the treatment team. The radiation oncologist plays an important role in treating patients with RIT and monitoring them for responses and adverse events after treatment.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Roger M. M.D., Brad M.D.,